Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ
Tải xuống
Tyrosine kinase inhibitors (TKIs) have become the mainstay of treatment for advanced renal cell carcinoma (RCC), but it has been unclear whether the antitumor effect of TKIs depends on the organ where the RCC metastasis is located. |